ScreenerHero

NBTX Nanobiotix S.A.

NAS · US · Healthcare · Biotechnology · nanobiotix.com
24.62USD-2.42%Mkt Cap: 1.25B $P/E: —

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.25B USD
Enterprise Value1.28B USD
Revenue (TTM)11.51M USD
Gross Profit11.51M USD
Net Income (TTM)-23.96M USD
Revenue/Share0.24 USD
Last Price24.62 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-150.66
PEG—
EV/EBITDA-42.89
EV/Revenue111.03
P/S111.65
P/B-34.10
EPS (TTM)-1.27
EPS (Forward)-0.17
52W Range
14.7823% of range57.14
52W High57.14 USD
52W Low14.78 USD
Profitability
Gross Margin100.00%
Oper. Margin-322.88%
EBITDA Margin-258.87%
Profit Margin-80.83%
ROE28.36%
ROA-35.36%
Growth
Revenue Growth-79.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.42M USD
CapEx (TTM)546.00K USD
FCF Margin-284.91%
FCF Yield-2.61%
Net Debt-4.28M USD
Net Debt/EBITDA0.14
Balance Sheet
Debt/Equity-1.13
Current Ratio1.44
Quick Ratio1.40
Book Value/Sh-0.74 USD
Cash/Share2.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)54.09 USD
Upside (mean)+119.7%
Target Range29.63 USD – 69.29 USD
29.63+119.7% to mean69.29
# Analysts3
Ownership
Shares Out.50.92M
Float35.15M
Insiders0.00%
Institutions11.95%
Short Interest
Short Ratio1.1d
Short % Float0.47%
Short % Out.0.35%
Shares Short175.99K
Short (prev mo.)133.29K
Technical
SMA 5037.54 (-34.4%)
SMA 20033.41 (-26.3%)
Beta0.59
S&P 52W Chg15.78%
Avg Vol (30d)149.49K
Avg Vol (10d)166.55K
Technical Indicators
RSI (14)24.3
MACD-3.5102
MACD Signal-2.6004
MACD Hist.-0.9098
BB Upper41.32 USD
BB Middle32.45 USD
BB Lower23.58 USD
BB Width54.65%
ATR (14)2.230 USD
Vol Ratio (20d)0.95x